FDA grants accelerated approval of Biogen’s treatment for a rare form of ALS


The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic lateral sclerosis, or ALS.

The accelerated program is used to approve drugs for serious conditions that have an unmet medical need, where a drug is shown to have an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients.


This article was originally published by Marketwatch.com. Read the original article here.

Previous article: FDA grants accelerated approval to Biogen’s treatment for rare form of ALS
Next articleMarket Extra: What’s next for stock market as small-cap index suffers its first ‘death cross’ since January 2022


Please enter your comment!
Please enter your name here